Aumed, a.s., Komořanská 326/63, 143 14 Praha - Modřany, Česká republika

+420 603 587 701 English

Successful completion of the TRIO project „Development of a new dosage form for oral vaccine administration”

lyof tablety - výsledek TRIA

AUMED, a.s. successfully completed a multi-year project of the research and development support program of the Ministry of Industry and Trade called TRIO. AUMED, a.s. implemented a three-year project in this program entitled “Development of a new dosage form for oral vaccine administration” (Project no.: FV 40365).

The aim of the project was a microbial vaccine in the form of a lyophilized tablet which intended for administration into the oral cavity. A newly innovated pertussis vaccine has been chosen as a model vaccine which was developed by the company AUMED, a.s. in recent years. AUMED, a.s. cooperates on this project with the Charles University, Faculty of Pharmacy in Hradec Králové (Department of Pharmaceutical Technology, Head of Department: doc. PharmDr. Zdeňka Šklubalová, Ph.D.).

The goals of the project have been achieved. Two types of lyophilized tablets were prepared. The prepared tablets were used for an accelerated and long-term stability study. Lyophilized tablets of both types remained stable throughout the accelerated study. Even after 12 months in the long-term stability study, the tablets remain stable.

The project met two main results – Z (tech) proven technology – Preparation of a human vaccine in the form of a lyophilized tablet as a new carrier and Z (semi-pilot) pilot plant – Design and construction of equipment for production.

AUMED, a.s. plans to implement the achieved results into practice. The product must first be subjected to preclinical testing and then to clinical evaluation. The lyophilized tablet can also be used as a carrier for other types of bacterial vaccines.

MORE ARTICLES

AUMED, a.s. received support for the development of a vaccine against Staphylococcus aureus

18. 12. 2023

AUMED received support for the project “Development of a new vaccine against Staphylococcus aureus”, registration number CZ.01.01.01/01/22_002/0000585. Staphylococcus aureus causes…

AUMED, a.s. received support for the development of a product for the supportive treatment of the skin in the case of atopic eczema

18. 12. 2023

AUMED received support for the project “Development of a preparation based on a cleansing spray intended for the supportive treatment…

AUMED participated in the immunology congress with great success

14. 11. 2023

Representatives of AUMED participated in the XL. Congress of Slovak and Czech allergists and clinical immunologists, which took place in…

Research projects of Aumed, a.s. are financed by the European Structural Funds and with financial support from the state budget through the Ministry of Industry and Trade. A complete list of all ongoing and completed projects with this support can be found here.

European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness


Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s